<DOC>
	<DOCNO>NCT00610441</DOCNO>
	<brief_summary>This Phase 2 multicenter , randomize , double-blind trial MK-8777 ( Org 26576 , SCH 900777 ) adult subject Attention-Deficit/Hyperactivity Disorder ( ADHD ) . MK-8777 placebo administer crossover fashion two 3-week treatment period . The two 3-week treatment period separate 2-week placebo washout period . The primary objective compare efficacy various dose MK-8777 placebo treatment ADHD symptom adult .</brief_summary>
	<brief_title>Dose Finding Study Adults With Attention-Deficit/Hyperactivity Disorder ( ADHD ) ( 174007/P05805/MK-8777-003 )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<criteria>1850 year , inclusive ; male ; female nonpregnant , nonlactating use acceptable method birth control ( intrauterine device , doublebarrier method , hormonal contraceptive ) ; female nonchildbearing potential ) surgically sterile ( tubal ligation , hysterectomy and/or bilateral oophorectomy ) provide documentation procedure operative report ultrasound scan , b ) postmenopausal great one year follicle stimulate hormone ( FSH ) level great equal 40 mIU/mL screening . All female must negative serum pregnancy test screening ; outpatient ; provide write informed consent fluent language investigator , able discontinue use psychotropic medication treatment ADHD symptom screen ; meet strict operational criterion adult ADHD accord Diagnostic Statistical Manual Mental Disorders , Fourth Edition ( DSMIVTRTM ) Clinical Global Impression ADHD score 4 high screening clinically significant concurrent medical condition ( endocrine , renal , respiratory , cardiovascular , hematological , immunological , cerebrovascular , neurological , anorexia , obesity malignancy ) become unstable may interfere interpretation safety efficacy evaluation . clinically significant abnormal laboratory , vital sign , physical examination , electrocardiogram ( ECG ) finding screen , opinion investigator , may interfere interpretation safety efficacy evaluation . history liver disease ( e.g. , cirrhosis , hepatitis ) , liver injury ; ( history hepatitis A great one year prior screen acceptable ) ; abnormal clinically significant finding screen liver laboratory parameter ( serum glutamicpyruvic transaminase [ SGPT ] , serum glutamic oxaloacetic transaminase [ SGOT ] , gammaglutamyltransferase [ GGT ] , lactate dehydrogenase [ LDH ] , bilirubin , albumin , protein , alkaline phosphatase ) ; seizure disorder beyond childhood take anticonvulsant prevent seizure ; know serological evidence human immunodeficiency virus ( HIV ) antibody ; positive test result screen hepatitis B surface antigen hepatitis A immunoglobulin M ( IgM ) antibodies hepatitis C total antibody ; pregnant confirm positive serum pregnancy test screening ; QTc value &gt; 450 msec screen use Fridericia 's QTc formula ; confirm positive result alcohol/drug screen test alcohol , illegal nonprescribed drug screen ( except marijuana/ tetrahydrocannabinol [ THC ] ) ; confirm positive result alcohol/drug screen retest marijuana/THC ; current lifetime history bipolar psychotic disorder ; current major depression disorder , obsessivecompulsive disorder , posttraumatic stress disorder , generalize anxiety disorder , panic disorder eat disorder ( also treat currently symptomatic ) ; current comorbid dysthymia social anxiety disorder currently treat psychotropic medication ; current untreated social anxiety disorder may interfere assessment ADHD investigator 's opinion ; present imminent risk selfharm harm others ; history significant suicide attempt , posse current risk attempt suicide , investigator 's opinion , base clinical interview response provide Beck Scale Suicidal Ideation ( BSS ) ; history jailing imprisonment past 6 month due worsen symptoms ADHD ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>randomize</keyword>
	<keyword>double blind</keyword>
	<keyword>placebo control</keyword>
</DOC>